Evaluating the quality of life for lymphoma patients on oral therapy
Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy
This study is trying to see how starting oral treatments for lymphoma affects the quality of life for patients over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 464 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | ibrutinib, acalabrutinib |
| Locations | 14 sites (Bayonne and 13 other locations) |
| Trial ID | NCT04985214 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life of patients with lymphomas who are starting oral therapies such as ibrutinib and venetoclax. It will follow a prospective longitudinal cohort design, collecting data from participants at the initiation of treatment and annually for five years. The study will also explore various factors that may influence quality of life, including biological and non-biological aspects. The research is conducted at a single center, the University Hospital in Toulouse, with additional data collection at affiliated hospitals.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are starting oral therapy for lymphomas and can understand the study's objectives.
Not a fit: Patients who are pregnant or under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into how oral therapies impact the quality of life for lymphoma patients, potentially guiding future treatment approaches.
How similar studies have performed: While there is limited data on the real-life impact of these oral therapies, similar studies have shown the importance of assessing quality of life in cancer treatment, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients included in the PK-E3i clinical study OR * Over the age of 18 * Patients with hemopathies and starting treatment with oral therapy (idelalisib, ibrutinib, venetoclax, lenalidomide, acalabrutinib...) * Be able to understand the objective and the constraints related to research * Patient having read the information notice and the non-objection form * Social Security affiliation Exclusion Criteria: * Pregnant women * Persons under legal protection of adults * Patients under judicial protection
Where this trial is running
Bayonne and 13 other locations
- CH de Bayonne — Bayonne, France (Recruiting)
- CHU Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
- CHU de Grenoble — Grenoble, France (Recruiting)
- CH Versailles — Le Chesnay, France (Recruiting)
- CH Le Mans — Le Mans, France (Recruiting)
- CHU de Limoges — Limoges, France (Recruiting)
- Centre Léon Bérard — Lyon, France (Recruiting)
- Institut Paoli Calmettes — Marseille, France (Recruiting)
- CHU de Montpellier — Montpellier, France (Recruiting)
- CHU de Nîmes — Nîmes, France (Recruiting)
- CH de Perpignan — Perpignan, France (Recruiting)
- Hospices Civils de Lyon — Pierre-Bénite, France (Recruiting)
- Loïc YSEBAERT — Toulouse 9, France (Recruiting)
- CHU de Tours — Tours, France (Recruiting)
Study contacts
- Principal investigator: Loïc YSEBAERT, Prof. — University Hospital, Toulouse
- Study coordinator: Loïc YSEBAERT, Prof.
- Email: ysebaert.loic@iuct-oncopole.fr
- Phone: 0531156351
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.